X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB STRIDES PHARMA SCIENCE UNICHEM LAB/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 284.8 70.2 405.8% View Chart
P/BV x 0.7 1.2 55.1% View Chart
Dividend Yield % 2.6 0.4 631.6%  

Financials

 UNICHEM LAB   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
UNICHEM LAB/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3821,147 33.3%   
Low Rs234642 36.5%   
Sales per share (Unadj.) Rs116.3317.2 36.7%  
Earnings per share (Unadj.) Rs-18.97.8 -241.2%  
Cash flow per share (Unadj.) Rs-11.725.1 -46.9%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %1.60.2 725.9%  
Book value per share (Unadj.) Rs381.0274.3 138.9%  
Shares outstanding (eoy) m70.3489.50 78.6%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x2.62.8 93.9%   
Avg P/E ratio x-16.3114.0 -14.3%  
P/CF ratio (eoy) x-26.235.7 -73.5%  
Price / Book Value ratio x0.83.3 24.8%  
Dividend payout %-26.425.5 -103.6%   
Avg Mkt Cap Rs m21,66880,058 27.1%   
No. of employees `0002.32.5 90.9%   
Total wages/salary Rs m2,0064,341 46.2%   
Avg. sales/employee Rs Th3,587.811,325.8 31.7%   
Avg. wages/employee Rs Th880.01,731.4 50.8%   
Avg. net profit/employee Rs Th-583.7280.1 -208.4%   
INCOME DATA
Net Sales Rs m8,18028,394 28.8%  
Other income Rs m610941 64.9%   
Total revenues Rs m8,79029,334 30.0%   
Gross profit Rs m-1,3203,965 -33.3%  
Depreciation Rs m5051,540 32.8%   
Interest Rs m801,962 4.1%   
Profit before tax Rs m-1,2951,403 -92.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-168 1.3%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m3397 34.3%   
Profit after tax Rs m-1,331702 -189.6%  
Gross profit margin %-16.114.0 -115.6%  
Effective tax rate %-2.66.9 -37.2%   
Net profit margin %-16.32.5 -658.0%  
BALANCE SHEET DATA
Current assets Rs m23,31824,836 93.9%   
Current liabilities Rs m4,63518,993 24.4%   
Net working cap to sales %228.420.6 1,109.9%  
Current ratio x5.01.3 384.7%  
Inventory Days Days12271 171.6%  
Debtors Days Days121113 107.1%  
Net fixed assets Rs m8,16334,289 23.8%   
Share capital Rs m141895 15.7%   
"Free" reserves Rs m26,66023,651 112.7%   
Net worth Rs m26,80124,546 109.2%   
Long term debt Rs m315,513 0.0%   
Total assets Rs m31,89065,437 48.7%  
Interest coverage x-15.21.7 -884.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.30.4 59.1%   
Return on assets %-3.94.1 -96.3%  
Return on equity %-5.02.9 -173.6%  
Return on capital %-4.56.9 -65.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35615,697 27.8%   
Fx outflow Rs m0735 0.0%   
Net fx Rs m4,35614,962 29.1%   
CASH FLOW
From Operations Rs m-1,1231,871 -60.1%  
From Investments Rs m16,4875,826 283.0%  
From Financial Activity Rs m-8,811-10,157 86.8%  
Net Cashflow Rs m6,552-2,615 -250.6%  

Share Holding

Indian Promoters % 50.1 27.7 180.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 37.8 39.9%  
FIIs % 3.0 8.6 34.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 25.9 122.4%  
Shareholders   20,176 56,241 35.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare UNICHEM LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Apr 18, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS